Aberrant Expression of MicroRNA-26b and Its Prognostic Potential in Human Cervical Cancer

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 Jul 21

PMID 26191262

Citations 20

Authors

Min Luo

Dongxiang Shen

Wei Wang

Jiang Xian

Affiliations

Soon will be listed here.

Abstract

Background: microRNA-26b (miR-26b) is reported to be downregulated in many human malignancies and function as a tumor suppressor. However, the roles of miR-26b expression in cervical cancer progression are unclear. The aim of this study was to investigate the clinicopathological or prognostic significance of miR-26b in human cervical cancer.

Methods: A cohort of 88 paired of cervical cancer and the adjacent normal cervical epithelial tissues were collected. Quantitative RT-PCR (qRT-PCR) assay was used to detect the expression of miR-26b and its correlations with clinicopathological factors were statistically analyzed. Finally, the survival was assessed by the Kaplan-Meier method and proportional hazards model.

Results: The expression level of miR-26b in cervical cancer tissues was significantly lower than that in the adjacent normal cervical tissues (P<0.001). Reduced miR-26b was observed to be significantly correlated with advanced FIGO stage, higher incidence of lymph node metastasis and recurrence of cervical cancer patients (P=0.002, 0.036 and 0.029, respectively). In addition, patients with low-miR-26b expression showed poorer recurrence-free survival (RFS) and overall survival (OS) than those with high-miR-26b expression (P=0.0043 and 0.0015, respectively). Furthermore, multivariate analyses demonstrated that low miR-26b expression was an independent prognostic factor for predicting the 5-year RFS and OS of cervical cancer patients (P=0.013 and 0.007, respectively).

Conclusion: Our results showed that reduced miR-26b was correlated with tumor development and poor prognosis in human cervical cancer. The status of miR-26b expression may be a potential prognostic biomarker for cervical cancer patients.

Citing Articles

Value of non-coding RNAs to assess lymph node status in cervical cancer.

Dabi Y, Favier A, Razakamanantsoa L, Suisse S, Marie Y, Touboul C Front Oncol. 2023; 13:1144672.

PMID: 37234986 PMC: 10206114. DOI: 10.3389/fonc.2023.1144672.

Rs1894720 polymorphism is associated with the risk of age-related cataract by regulating the proliferation of epithelial cells in the lens via the signalling pathway of MIAT/miR-26b/BCL2L2.

Li Y, Zhang W, Ke H, Wang Y, Duan C, Zhu Q Arch Med Sci. 2022; 18(1):223-236.

PMID: 35154542 PMC: 8826737. DOI: 10.5114/aoms.2020.91533.

Association study of relationships of polymorphisms in the miR-21, miR-26b, miR-221/222 and miR-126 genes with cervical intraepithelial neoplasia and cervical cancer.

Yang J, Yan Z, Wang Y, Xu J, Li R, Li C BMC Cancer. 2021; 21(1):997.

PMID: 34488676 PMC: 8422721. DOI: 10.1186/s12885-021-08743-2.

Role of microRNAs in Predicting the Prognosis of Cervical Cancer Cases: A Systematic Review and Meta-Analysis.

Sabeena S, Ravishankar N Asian Pac J Cancer Prev. 2021; 22(4):999-1006.

PMID: 33906290 PMC: 8325113. DOI: 10.31557/APJCP.2021.22.4.999.

miR-193a-3p Promotes the Invasion, Migration, and Mesenchymal Transition in Glioma through Regulating BTRC.

Zhou D, Li H, Liu W, Zhang L, Zheng Q, Bai J Biomed Res Int. 2021; 2021:8928509.

PMID: 33628829 PMC: 7886567. DOI: 10.1155/2021/8928509.

References

Ke G, Liang L, Yang J, Huang X, Han D, Huang S . MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. Oncogene. 2012; 32(25):3019-27. DOI: 10.1038/onc.2012.323. View

Liu X, Li X, Zhang B, Liang Y, Zhou C, Cao D . MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett. 2011; 585(9):1363-7. DOI: 10.1016/j.febslet.2011.04.018. View

Xie J, Chen M, Zhou J, Mo M, Zhu L, Liu Y . miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol Rep. 2014; 31(4):1715-22. DOI: 10.3892/or.2014.3052. View

He L, Hannon G . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31. DOI: 10.1038/nrg1379. View

Lee J, Choi C, Choi J, Park Y, Kim S, Hwang S . Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res. 2008; 14(9):2535-42. DOI: 10.1158/1078-0432.CCR-07-1231. View

Hou T, Ou J, Zhao X, Huang X, Huang Y, Zhang Y . MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1. Br J Cancer. 2014; 110(5):1260-8. PMC: 3950858. DOI: 10.1038/bjc.2013.829. View

Long M, Wu F, Li P, Liu M, Li X, Tang H . MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Lett. 2012; 324(2):186-96. DOI: 10.1016/j.canlet.2012.05.022. View

Li J, Kong X, Zhang J, Luo Q, Li X, Fang L . MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer. Cancer Cell Int. 2013; 13(1):7. PMC: 3599806. DOI: 10.1186/1475-2867-13-7. View

Moore D . Cervical cancer. Obstet Gynecol. 2006; 107(5):1152-61. DOI: 10.1097/01.AOG.0000215986.48590.79. View

10.

Fang Y, Yao Q, Chen Z, Xiang J, William F, Gibbs R . Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine. Med Sci Monit. 2013; 19:916-26. PMC: 3818103. DOI: 10.12659/MSM.889636. View

11.

Zhang Z, Kim K, Li X, Moreno M, Sharp T, Goodheart M . MicroRNA-26b represses colon cancer cell proliferation by inhibiting lymphoid enhancer factor 1 expression. Mol Cancer Ther. 2014; 13(7):1942-51. PMC: 4090280. DOI: 10.1158/1535-7163.MCT-13-1000. View

12.

Wen S, Lin Y, Yu Y, Cao S, Zhang R, Yang X . miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer. Oncogene. 2014; 34(6):717-25. DOI: 10.1038/onc.2014.9. View

13.

Park H, Lee M, Jeong J, Choi M, Jung S, Joo W . Dysregulated microRNA expression in adenocarcinoma of the uterine cervix: clinical impact of miR-363-3p. Gynecol Oncol. 2014; 135(3):565-72. DOI: 10.1016/j.ygyno.2014.09.010. View

14.

Li J, Li X, Kong X, Luo Q, Zhang J, Fang L . MiRNA-26b inhibits cellular proliferation by targeting CDK8 in breast cancer. Int J Clin Exp Med. 2014; 7(3):558-65. PMC: 3992393. View

15.

McManus M . MicroRNAs and cancer. Semin Cancer Biol. 2003; 13(4):253-8. DOI: 10.1016/s1044-579x(03)00038-5. View

16.

Shen G, Lin Y, Yang X, Zhang J, Xu Z, Jia H . MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X. BMC Cancer. 2014; 14:393. PMC: 4062892. DOI: 10.1186/1471-2407-14-393. View

17.

Wang N, Zhou Y, Zheng L, Li H . MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A. Gynecol Oncol. 2014; 134(1):129-37. DOI: 10.1016/j.ygyno.2014.04.047. View

18.

Zhu J, Zheng Z, Wang J, Sun J, Wang P, Cheng X . Different miRNA expression profiles between human breast cancer tumors and serum. Front Genet. 2014; 5:149. PMC: 4033838. DOI: 10.3389/fgene.2014.00149. View

19.

Ying S, Chang D, Lin S . The MicroRNA. Methods Mol Biol. 2012; 936:1-19. DOI: 10.1007/978-1-62703-083-0_1. View

20.

Carthew R . Gene regulation by microRNAs. Curr Opin Genet Dev. 2006; 16(2):203-8. DOI: 10.1016/j.gde.2006.02.012. View